Switch theme
Sign up to access all valuation multiples
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
2005
209
LTM Revenue $266M
LTM EBITDA -$39.9M
$8.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Verona Pharma has a last 12-month revenue (LTM) of $266M and a last 12-month EBITDA of -$39.9M.
In the most recent fiscal year, Verona Pharma achieved revenue of $42.3M and an EBITDA of -$139M.
Verona Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Verona Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $266M | XXX | $42.3M | XXX | XXX | XXX |
| Gross Profit | $249M | XXX | $39.7M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 94% | XXX | XXX | XXX |
| EBITDA | -$39.9M | XXX | -$139M | XXX | XXX | XXX |
| EBITDA Margin | -15% | XXX | -328% | XXX | XXX | XXX |
| EBIT | -$41.9M | XXX | -$151M | XXX | XXX | XXX |
| EBIT Margin | -16% | XXX | -357% | XXX | XXX | XXX |
| Net Profit | -$65.0M | XXX | -$173M | XXX | XXX | XXX |
| Net Margin | -24% | XXX | -410% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Verona Pharma's stock price is $105.
Verona Pharma has current market cap of $9.0B, and EV of $8.8B.
See Verona Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.8B | $9.0B | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Verona Pharma has market cap of $9.0B and EV of $8.8B.
Verona Pharma's trades at 208.0x EV/Revenue multiple, and -63.5x EV/EBITDA.
Equity research analysts estimate Verona Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Verona Pharma has a P/E ratio of -137.6x.
See valuation multiples for Verona Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.0B | XXX | $9.0B | XXX | XXX | XXX |
| EV (current) | $8.8B | XXX | $8.8B | XXX | XXX | XXX |
| EV/Revenue | 33.0x | XXX | 208.0x | XXX | XXX | XXX |
| EV/EBITDA | -220.2x | XXX | -63.5x | XXX | XXX | XXX |
| EV/EBIT | -209.9x | XXX | -58.2x | XXX | XXX | XXX |
| EV/Gross Profit | 35.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -137.6x | XXX | -51.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -71.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVerona Pharma's last 12 month revenue growth is 137%
Verona Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.9M for the same period.
Verona Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Verona Pharma's rule of X is 327% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Verona Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 137% | XXX | 329% | XXX | XXX | XXX |
| EBITDA Margin | -15% | XXX | -328% | XXX | XXX | XXX |
| EBITDA Growth | -1163% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -191% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 327% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 105% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 451% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Verona Pharma acquired XXX companies to date.
Last acquisition by Verona Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Verona Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Verona Pharma founded? | Verona Pharma was founded in 2005. |
| Where is Verona Pharma headquartered? | Verona Pharma is headquartered in United States of America. |
| How many employees does Verona Pharma have? | As of today, Verona Pharma has 209 employees. |
| Who is the CEO of Verona Pharma? | Verona Pharma's CEO is Dr. David Zaccardelli, Pharm.D.. |
| Is Verona Pharma publicy listed? | Yes, Verona Pharma is a public company listed on NAS. |
| What is the stock symbol of Verona Pharma? | Verona Pharma trades under VRNA ticker. |
| When did Verona Pharma go public? | Verona Pharma went public in 2017. |
| Who are competitors of Verona Pharma? | Similar companies to Verona Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Verona Pharma? | Verona Pharma's current market cap is $9.0B |
| What is the current revenue of Verona Pharma? | Verona Pharma's last 12 months revenue is $266M. |
| What is the current revenue growth of Verona Pharma? | Verona Pharma revenue growth (NTM/LTM) is 137%. |
| What is the current EV/Revenue multiple of Verona Pharma? | Current revenue multiple of Verona Pharma is 33.0x. |
| Is Verona Pharma profitable? | Yes, Verona Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Verona Pharma? | Verona Pharma's last 12 months EBITDA is -$39.9M. |
| What is Verona Pharma's EBITDA margin? | Verona Pharma's last 12 months EBITDA margin is -15%. |
| What is the current EV/EBITDA multiple of Verona Pharma? | Current EBITDA multiple of Verona Pharma is -220.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
